학술논문
Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD.
Document Type
Article
Author
Source
Subject
*ANKLE brachial index
*PERIPHERAL vascular diseases
*CORONARY artery disease
*RIVAROXABAN
*ASPIRIN
*MAJOR adverse cardiovascular events
*MYOCARDIAL infarction
*
*
*
*
*
*
Language
ISSN
0009-7322
Abstract
The article discusses the results of the VOYAGER PAD clinical trial, which investigated the use of low-dose rivaroxaban plus aspirin in patients with peripheral artery disease (PAD) undergoing lower extremity revascularization. The trial found that rivaroxaban reduced the risk of major adverse cardiovascular events (MACE) and major adverse limb events (MALE) by 15% compared to placebo. The study also examined the effects of rivaroxaban in patients with concomitant coronary artery disease (CAD) and found consistent benefits in both groups. However, the risk of major bleeding was higher in patients with CAD. The findings suggest that rivaroxaban plus aspirin may be an effective treatment option for patients with PAD, but shared decision-making between clinicians and patients is important. [Extracted from the article]